Myriad Genetics 10-Qquarter ended 2026-09-30

Executive Summary

Myriad Genetics sells genetic tests for cancer, mental health and prenatal care to patients through healthcare providers, earning revenue from test reimbursement. It is concentrating on Cancer Care Continuum and Mental Health while agreeing, after quarter-end, to sell specified Prenatal Health assets to Labcorp for $210M plus inventory value. Q3 revenue fell 1.5% as prenatal weakness outweighed modest growth elsewhere, while commercial spending widened losses. The sale could fund cancer-testing investment and debt repayment, but investors must weigh that opportunity against reimbursement pressure and revenue covenants that would remain after the divestiture.

What's Happening in the Business

The planned prenatal divestiture reshapes Myriad’s portfolio. The 10/19/2026 agreement includes Foresight, Prequel, FirstGene and SneakPeek, following FirstGene’s launch in July. Management expects closing by early 2027, subject to regulatory approvals and other conditions. Proceeds could support operations, debt repayment and Cancer Care Continuum investment, but selling the business also removes revenue before shared costs necessarily fall.

Cancer testing illustrates the remaining business’s challenge: demand is growing faster than revenue. Q3 Cancer Care Continuum volume increased 4% to 98,000 tests, but revenue per test fell 3%; over nine months, volume rose 7% while revenue per test fell 9%, primarily because of lower reimbursement.

Management favors organic R&D and new products. In October, Myriad announced a collaboration with SOPHiA GENETICS to advance prostate genomic instability score technology with AstraZeneca.

Key Financial Highlights

• Prenatal and mental health demand: Prenatal volume fell 11% in both periods, making it the principal revenue drag. Mental Health’s Q3 volume rose 3% to 141,000 tests, but revenue growth slowed below its nine-month pace.
• Commercial spending: Q3 sales and marketing rose 18% to $83.9M, including $10.6M more personnel costs; the investment has not yet produced company-wide growth.
• Earnings comparability: Nine-month impairment charges fell to $5.4M from $317M. The prior year also benefited from a $29.6M discrete tax benefit, while interest expense increased to $12.3M from $6.1M.
• Cash and funding: Nine-month operating cash use was $30.5M vs $8.8M, despite favorable working-capital changes. It was smaller than the same-period net loss partly because earnings included noncash costs, including $22.9M of stock-based compensation. Capital investment consumed another $11.8M; cash fell 28% from year-end to $107M. Funded loan principal was $125M at a 10.2% variable interest rate.

Risk Assessment

• Reimbursement and collections: Revised collection estimates reduced nine-month revenue by $10.3M for previously delivered tests, showing that recorded sales remain exposed to payer denials, disputes and refunds.
• Sale execution and stranded costs: Regulatory delays could defer proceeds, while completion removes prenatal revenue without guaranteeing matching shared-cost reductions; retained billing liabilities and indemnities could further reduce benefits.
• Covenant and liquidity pressure: The trailing-12-month revenue covenant survives the sale against a lower revenue base; a breach could accelerate borrowings, while continuing cash use could restrict investment.
• Litigation: Most of Myriad’s dismissal motion in the False Claims Act case was denied, and the EndoPredict patent appeal could create exposure under its buyer indemnity despite no material legal accrual.

This 10-Q lists only the risk factors that changed since the annual report. Full list: FY2025 10-K.

What to Watch

• Prenatal exit: Management expects closing by early 2027. Later filings should establish whether proceeds arrive and shared costs fall, or whether delays, retained liabilities and transition costs weaken the benefit.
• Cancer monetization: Nine-month test volume grew while reimbursement fell. Revenue per test stabilizing alongside volume growth would validate the focus; continued erosion would undermine it.
• Mental Health growth: Q3 growth slowed below the nine-month rate. Sustained test growth and reimbursement would support diversification; further slowing would leave cancer testing carrying more of the recovery.
• Cash and debt after closing: Watch whether proceeds reduce expensive borrowing while preserving investment capacity, or recurring cash burn consumes them and leaves covenant pressure unresolved.